INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG).

Lam, Lyn Ley; Pavlakis, Nick; Shitara, Kohei; Sjoquist, Katrin M; Martin, Andrew J; Yip, Sonia; Kang, Yoon-Koo; Bang, Yung-Jue; Chen, Li-Tzong; Moehler, Markus; Bekaii-Saab, Tanios; Alcindor, Thierry; O'Callaghan, Christopher J; Tebbutt, Niall C; Hague, Wendy; Chan, Howard; Rha, Sun Young; Lee, Keun-Wook; Gebski, Val; Jaworski, Anthony; Zalcberg, John; Price, Timothy; Simes, John; Goldstein, David

doi:10.1186/s12885-023-10642-7

Title

INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG).

Publication Date

2023-02-22

Author(s)

Lam, Lyn Ley

Pavlakis, Nick

Shitara, Kohei

Sjoquist, Katrin M

Martin, Andrew J

Yip, Sonia

Kang, Yoon-Koo

Bang, Yung-Jue

Chen, Li-Tzong

Moehler, Markus

Bekaii-Saab, Tanios

Alcindor, Thierry

O'Callaghan, Christopher J

Tebbutt, Niall C

Hague, Wendy

Chan, Howard

Rha, Sun Young

Lee, Keun-Wook

Gebski, Val

Jaworski, Anthony

Zalcberg, John

Price, Timothy

Simes, John

Goldstein, David

Subject

Advanced gastro-oesophageal cancer

Clinical trial

Nivolumab

Regorafenib

Tyrosine kinase inhibitor

Type of document

Journal Article

OrcId

#PLACEHOLDER_PARENT_METADATA_VALUE#

DOI

10.1186/s12885-023-10642-7

Abstract

Advanced gastro-oesophageal cancer (AGOC) carries a poor prognosis. No standard of care treatment options are available after first and second-line therapies. Regorafenib is an oral multi-targeted tyrosine kinase inhibitor targeting angiogenic, stromal, and oncogenic receptor tyrosine kinases. Regorafenib 160 mg daily prolonged progression free survival compared to placebo (INTEGRATE, phase 2). Regorafenib 80 mg daily in combination with nivolumab 3 mg/kg showed promising objective response rates (REGONIVO).

Link

link

Citation

BMC cancer 2023; 23(1)

Jornal Title

BMC cancer

ISSN

1471-2407

Austin Health

Files: